A new analysis of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, presented at the 11th International St Gallen Oncology Conference, Switzerland, shows that during the first two years after surgery, anastrozole is superior to tamoxifen at reducing the risk of breast cancer returning in postmenopausal women with hormone receptor positive early breast cancer (n=5,216). Anastrozole has consistently demonstrated superiority over tamoxifen, both during the five-year treatment period and beyond treatment completion.
The details can be read here.
No comments:
Post a Comment